Revolution Medicines Launches Rasonque at $39,800; Guggenheim Lifts PT to $275
RVMD has more than doubled off its 52-week low of $37.56.
Summary
Revolution Medicines has launched Rasonque (daraxonrasib) in the U.S. at a price of $39,800 per 30-day supply, following FDA approval on August 26. The company has established patient support programs and co-pay assistance to facilitate payer adoption. Separately, Guggenheim raised its price target on RVMD to $275 from $240, reflecting increased confidence in the commercial opportunity. The launch price is a key data point for revenue modeling, and the analyst action adds to positive sentiment. Watch for initial prescription trends and payer coverage decisions in the coming weeks.
At the time of this announcement, RVMD was trading at $208.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.6B. The 52-week trading range was $37.56 to $224.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.